You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Selective activity over a constitutively active RET‐variant of the oral multikinase inhibitor dovitinib: Results of the CNIO‐BR002 phase I‐trial
|
|---|---|
| Published in |
Molecular Oncology, July 2014
|
| DOI | 10.1016/j.molonc.2014.07.005 |
| Pubmed ID | |
| Authors |
Miguel Quintela-Fandino, Maria J. Bueno, Luis Lombardia, Marta Gil, Antonio Gonzalez-Martin, Raul Marquez, Raquel Bratos, Juan Guerra, Eugene Tan, Antonio Lopez, Ramon Colomer, Ramon Salazar |
| Abstract |
Background: Given our preclinical data showing synergy between dovitinib and paclitaxel in preclinical models we conducted this phase I trial aiming to define the recommended phase II-dose (RP2D) on the basis of toxicity and pharmacodynamic criteria while searching for genetic variants that could sensitize patients to the regimen under study. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 33 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 15% |
| Student > Ph. D. Student | 4 | 12% |
| Student > Master | 3 | 9% |
| Student > Doctoral Student | 3 | 9% |
| Student > Bachelor | 3 | 9% |
| Other | 7 | 21% |
| Unknown | 8 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 6 | 18% |
| Medicine and Dentistry | 4 | 12% |
| Agricultural and Biological Sciences | 4 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 4 | 12% |
| Unknown | 10 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 August 2015.
All research outputs
#3,530,095
of 24,477,448 outputs
Outputs from Molecular Oncology
#260
of 1,635 outputs
Outputs of similar age
#30,998
of 209,118 outputs
Outputs of similar age from Molecular Oncology
#3
of 41 outputs
Altmetric has tracked 24,477,448 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,635 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,118 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.